PTC Therapeutics (PTCT) News
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
56.42-1.91 (-3.27%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PTCT news summary
We found 10 recent headlines mentioning PTC Therapeutics (PTCT): 0 in the past week and 9 in the past 30 days, most often from Nasdaq, PR Newswire, Investing.com. For price context, PTCT is down 3.27% at $56.42. The most recent story, "PTC Therapeutics, Inc. Announces $500.0 Million Share Repurchase Program", was published by Nasdaq on Nov 3, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest PTC Therapeutics headlines
- PTC Therapeutics, Inc. Announces $500.0 Million Share Repurchase ProgramPTC Therapeutics, Inc. announced that on November 3, 2026, its Board of Directors authorized a share repurchase program under which the Company may repurchase up to $500.0 million of the…Nasdaq
- Why is PTC Therapeutics stock surging today?Investing.com
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%(RTTNews) - Healthcare stocks moved higher following quarterly earnings reports, acquisition news and capital allocation updates. SI-BONE and Neurocrine Biosciences advanced after reporting…NasdaqNBIX, PTCT, RMTI, SIBN
- PTC Therapeutics sets $500M stock buyback planSeeking Alpha
- PTC Therapeutics Board Approves $500 Mln Share Buyback(RTTNews) - PTC Therapeutics, Inc. (PTCT), a biopharmaceutical company, said Tuesday that its Board of Directors has authorized a share repurchase program of up to $500 million.NasdaqPTCT, LEN.B
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of…PR Newswire
- PTC Therapeutics (PTCT) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- PTC Therapeutics, Inc. Reports Q3 2026 Total Revenue of $358 million and Raises Full-Year GuidancePTC Therapeutics, Inc. reported total revenue of $358 million for the third quarter of 2026, including $276 million of product revenue. Sephience generated Q3 2026 revenue of $182 million, which…Nasdaq
- PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with…PR Newswire
- ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last?ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.NasdaqIBRX, PTCT